A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

Exclusion Criteria

• •Women who are pregnant, lactating, breastfeeding or planning pregnancy during the study period
• •Any of the following specific CLE subtypes in isolation: acute cutaneous lupus erythematosus (ACLE), lupus tumidus, lupus (profundus) panniculitis, chilblains
• •Drug-induced CLE and/or drug-induced systemic lupus erythematosus (SLE)
• •Antiphospholipid antibody syndrome, serious thrombotic event or unexplained pregnancy loss within 1 year before the screening visit
• •History of 3 or more unexplained consecutive pregnancy losses
• •Active severe or unstable neuropsychiatric SLE
• •Other autoimmune diseases or non-SLE driven inflammatory joint or skin disease or overlap syndromes as primary disease that in the opinion of the investigator will significantly impact the assessment of CLE/SLE disease manifestations and activity